NASDAQ:ATXI - Avenue Therapeutics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$5.25 +0.32 (+6.49 %)
(As of 12/12/2018 08:47 AM ET)
Previous Close$4.93
Today's Range$4.86 - $5.46
52-Week Range$2.08 - $6.00
Volume72,623 shs
Average Volume48,004 shs
Market Capitalization$52.78 million
P/E Ratio-2.97
Dividend YieldN/A
Beta-2.04
Avenue Therapeutics, Inc., a specialty pharmaceutical company, acquires, licenses, develops, and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, which is in Phase III clinical trials to treat moderate to moderately severe post-operative pain. The company was founded in 2015 and is based in New York, New York.

Receive ATXI News and Ratings via Email

Sign-up to receive the latest news and ratings for ATXI and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ATXI
Previous Symbol
CUSIPN/A
Phone781-652-4500

Debt

Debt-to-Equity RatioN/A
Current Ratio2.14
Quick Ratio2.14

Price-To-Earnings

Trailing P/E Ratio-2.97
Forward P/E Ratio-2.40
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book Value$1.89 per share
Price / Book2.78

Profitability

EPS (Most Recent Fiscal Year)($1.77)
Net Income$-12,250,000.00
Net MarginsN/A
Return on Equity-261.40%
Return on Assets-183.17%

Miscellaneous

Employees2
Outstanding Shares10,660,000
Market Cap$52.78 million
OptionableNot Optionable

Avenue Therapeutics (NASDAQ:ATXI) Frequently Asked Questions

What is Avenue Therapeutics' stock symbol?

Avenue Therapeutics trades on the NASDAQ under the ticker symbol "ATXI."

How were Avenue Therapeutics' earnings last quarter?

Avenue Therapeutics Inc (NASDAQ:ATXI) announced its quarterly earnings results on Tuesday, August, 14th. The company reported ($0.45) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.68) by $0.23. View Avenue Therapeutics' Earnings History.

When is Avenue Therapeutics' next earnings date?

Avenue Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, March 7th 2019. View Earnings Estimates for Avenue Therapeutics.

What price target have analysts set for ATXI?

2 Wall Street analysts have issued twelve-month price targets for Avenue Therapeutics' stock. Their forecasts range from $10.00 to $11.00. On average, they expect Avenue Therapeutics' share price to reach $10.50 in the next twelve months. This suggests a possible upside of 100.0% from the stock's current price. View Analyst Price Targets for Avenue Therapeutics.

What is the consensus analysts' recommendation for Avenue Therapeutics?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Avenue Therapeutics in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Avenue Therapeutics.

Has Avenue Therapeutics been receiving favorable news coverage?

News stories about ATXI stock have been trending positive this week, InfoTrie Sentiment reports. The research group rates the sentiment of media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Avenue Therapeutics earned a daily sentiment score of 2.3 on InfoTrie's scale. They also gave news stories about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next few days.

Who are some of Avenue Therapeutics' key competitors?

Who are Avenue Therapeutics' key executives?

Avenue Therapeutics' management team includes the folowing people:
  • Dr. Lindsay Allan Rosenwald, Exec. Chairman (Age 63)
  • Dr. Lucy Lu, Pres, CEO & Director (Age 43)
  • Mr. Joseph Walter Vazzano, VP of Fin. & Accounting, Principal Financial Officer and controller (Age 34)
  • Dr. Scott A. Reines, Interim Chief Medical Officer (Age 71)

When did Avenue Therapeutics IPO?

(ATXI) raised $30 million in an IPO on Tuesday, June 27th 2017. The company issued 5,000,000 shares at a price of $5.00-$7.00 per share. Oppenheimer acted as the underwriter for the IPO and National Securities Corp. was co-manager.

How do I buy shares of Avenue Therapeutics?

Shares of ATXI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Avenue Therapeutics' stock price today?

One share of ATXI stock can currently be purchased for approximately $5.25.

How big of a company is Avenue Therapeutics?

Avenue Therapeutics has a market capitalization of $52.78 million. The company earns $-12,250,000.00 in net income (profit) each year or ($1.77) on an earnings per share basis. Avenue Therapeutics employs 2 workers across the globe.

What is Avenue Therapeutics' official website?

The official website for Avenue Therapeutics is http://www.avenuetx.com.

How can I contact Avenue Therapeutics?

Avenue Therapeutics' mailing address is 2 GANSEVOORT STREET 9TH FLOOR, NEW YORK NY, 10014. The company can be reached via phone at 781-652-4500 or via email at [email protected]


MarketBeat Community Rating for Avenue Therapeutics (NASDAQ ATXI)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  105 (Vote Outperform)
Underperform Votes:  124 (Vote Underperform)
Total Votes:  229
MarketBeat's community ratings are surveys of what our community members think about Avenue Therapeutics and other stocks. Vote "Outperform" if you believe ATXI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ATXI will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/12/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel